Lv3
390 积分 2022-09-13 加入
Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
9天前
已完结
Spatial immune scoring system predicts hepatocellular carcinoma recurrence
14天前
已完结
Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
25天前
已完结
Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors – a systematic review and meta-analysis
25天前
已完结
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma
1个月前
已完结
Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: Extending the indication for ablation?
1个月前
已完结
Clinical evaluation of percutaneous endovascular radiofrequency ablation for portal vein tumor thrombus: experience in 120 patients
1个月前
已完结
Comprehensive review of hepatocellular carcinoma with portal vein tumor thrombus: State of art and future perspectives
1个月前
已完结
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison
1个月前
已完结
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma
1个月前
已完结
皖公网安备34019202002308
